CRVS
Corvus Pharmaceuticals, Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Mar 12 ▲ Corvus Pharmaceuticals reported financial results for Q4 and full ye…
- Apr 17 Goldman Sachs initiates
- Apr 21 FDA: Corvus Pharmaceuticals to Host Investor and Analyst Meetin…
- May 14 ▲ Corvus Pharmaceuticals presented final Phase 1 data for soquelitinib…
- May 18 ▲ 1 insider buy $83.5K at $12.04
- Jun 11 ▲ 1 insider buy $250.2K at $11.53
- Aug 21 ▲ A strong institutional cluster formed in CRVS during 2026-Q2, with 1…
- Sep 30 FDA: Corvus Pharmaceuticals Announces Initiation of Phase 1b Cl…
- Nov 4 FDA: Corvus Pharmaceuticals Announces Initial Data from Soqueli…
- Nov 5 ▼ Earnings: CRVS Q3 2026 Earnings: EPS $-0.22 (-7.1% vs est)
- Nov 11 to Nov 13 ▲ 3 days of insider buys: $50.5K by 1 insider, avg $11.22
Signal stack
Where each data set points today.
- InsidersBULLISH
3 insiders bought $384.2K at an average $11.59. No open-market sales. Price is 9% below their cost.
- InstitutionsMIXED
Q3 2026: 22 added (1 new), 15 trimmed or exited. Largest new: Fisher Asset Management $12.0M.
- EstimatesFALLING
Current-quarter EPS estimate −$0.228 → −$0.235 over 90 days. 0 up, 1 down in 30 days.
- Short sellersSTEADY
Short interest −1.2% to 17.76M shares. 18.9 days to cover, ≈21.1% of shares.
- TrendRANGE
5% below its 50-day average.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| STATE STREET CORP | TRIM | $38.4M |
| Fisher Asset Management, LLC | NEW | $12.0M |
| MORGAN STANLEY | TRIM | $9.1M |
| Connor, Clark & Lunn Investment Management Ltd. | ADD | $4.9M |
| VOYA INVESTMENT MANAGEMENT LLC | ADD | $2.3M |
| BARCLAYS PLC | TRIM | $2.2M |
| SEI INVESTMENTS CO | DOUBLED | $2.1M |
| Squarepoint Ops LLC | DOUBLED | $1.5M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
Last action Apr 2026Price is below the lowest target. Median implies +183%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Apr 17, 2026 | Goldman Sachs INITIATE | Buy |
| Mar 13, 2026 | Oppenheimer REITERATE | Outperform |
| Jan 22, 2026 | Jefferies MAINTAIN | Buy |
| Jan 21, 2026 | Oppenheimer MAINTAIN | Outperform |
| Jan 21, 2026 | Barclays MAINTAIN | Overweight |
| Jan 20, 2026 | HC Wainwright & Co. MAINTAIN | Buy |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Arcara Jeffrey Chief Business Officer Nov 13, 2026 | BUY | $5.2K |
Arcara Jeffrey Chief Business Officer Nov 13, 2026 | BUY | $5.4K |
Arcara Jeffrey Chief Business Officer Nov 12, 2026 | BUY | $5.5K |
Arcara Jeffrey Chief Business Officer Nov 11, 2026 | BUY | $34.4K |
Thompson Peter A. Director Jun 11, 2026 | AWARD | 15,000 sh |
Grais Linda Director Jun 11, 2026 | AWARD | 15,000 sh |
CLARK IAN T Director Jun 11, 2026 | AWARD | 15,000 sh |
Moore David Scott Director Jun 11, 2026 | BUY | $250.2K |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | -$0.23 | -$0.24–-$0.22 | -3.3% | $0.00 |
| Next Q | -$0.27 | -$0.29–-$0.25 | -2.5% | $0.00 |
| Current FY | -$0.80 | -$0.81–-$0.79 | -3.2% | $0.00 |
| Next FY | -$1.10 | -$1.31–-$0.87 | -3.0% | $1.6M |
Short side
FINRA· Oct 30, 2026SecBot reports
10 filings · 5 press releases · 2 bullish · 0 bearish · 8 neutral- NEUTRAL INSIDER-BUYNov 13, 2026
Chief Business Officer Jeffrey Arcara purchased a total of $50K in CRVS shares over four…
The CBO's $50K purchase is small relative to market cap and does not signal a material change in outlook. Monitor next pipeline data readouts (Angel Pharma topline March 2027, HS trial data 1H 2027)…
- NEUTRAL SC 13GNov 10, 2026
State Street Corp filed a Schedule 13G disclosing a passive 5%+ stake in Corvus Pharmaceuticals as…
State Street's slightly increased passive stake is routine for a large index/asset manager. No change in investment thesis. Monitor for any future 13D conversion or material changes in ownership by…
- NEUTRAL 8-KNov 5, 2026
Corvus Pharmaceuticals reported Q3 2026 net loss of $20.3M, wider than the $10.2M loss in Q3 2025…
Monitor upcoming data catalysts: Angel Pharma cohort 1 atopic dermatitis topline in March 2027, HS Phase 1b initial data in 1H 2027, and ALPS ASH poster presentation in December 2026. Cash runway…
- NEUTRAL PRESS-RELEASENov 5, 2026
Corvus Pharmaceuticals reported Q3 2026 net loss of $20.3M ($0.22 per share), wider than the…
Monitor upcoming data readouts: Angel Pharma cohort 1 topline in March 2027, HS initial data in 1H 2027, and ASH presentation in December 2026 for ALPS data. Cash runway into Q2 2028 reduces…
All CRVS filing & press-release reports (15)
- INSIDER-BUY reportNov 13, 2026
- SC 13G reportNov 10, 2026
- PRESS-RELEASE reportNov 5, 2026
- 8-K reportNov 5, 2026
- PRESS-RELEASE reportNov 4, 2026
- PRESS-RELEASE reportSep 30, 2026
- INST-CLUSTER reportAug 21, 2026
- 8-K reportJul 22, 2026
- INST-CLUSTER reportJun 11, 2026
- 8-K reportMay 14, 2026
- 8-K reportMay 7, 2026
- DEFA14A reportApr 24, 2026
- PRESS-RELEASE reportApr 21, 2026
- PRESS-RELEASE reportMar 12, 2026
- PRESS-RELEASE reportMar 5, 2026